Patents Examined by Patrick Lewis
  • Patent number: 10633328
    Abstract: This invention relates to polyetheramines based on 1,3-dialcohols, in particular to an etheramine mixture comprising at least 90% by weight, based on the total weight of the etheramine mixture, of anamine of Formula (I) and/or (II), wherein R1-R12 are independently selected from H, alkyl, cycloalkyl, aryl, alkylaryl, or arylalkyl, wherein at least one of R1-R6 and at least one of R7-R12 is different from H, wherein A1-A9 are independently selected from linear or branched alkylenes having 2 to 18 carbon atoms, preferably 2-10 carbon atoms, most preferably 2-5 carbon atoms, wherein Z1-Z4 are independently selected from OH or NH2, wherein at least one of Z1-Z2 and at least one of Z3-Z4 is NH2, and wherein the sum of x+y is in the range of from 2 to 200, wherein x?1 and y?1; and x1+y1 is in the range of from 2 to 200, preferably 2-20, most preferably 2-10, wherein x1?1 and y1?1.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: April 28, 2020
    Assignee: BASF SE
    Inventors: Sophia Ebert, Björn Ludolph, Christof W. Wigbers, Steffen Maas, Frank Huelskoetter, Stefano Scialla, Dieter Boeckh, Kevin Christmas, Amy Eichstadt Waun, Brian J. Loughnane, Darren Rees, Christian Eidamshaus, Monika Charrak, Alexander Panchenko
  • Patent number: 9932363
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection, with a nucleoside, a nucleotide and an analog thereof.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: April 3, 2018
    Assignee: Alios BioPharma, Inc.
    Inventors: Natalia Dyatkina, Guangyi Wang, Leonid Beigelman, Vivek Kumar Rajwanshi
  • Patent number: 9920319
    Abstract: The present invention provides novel chiral serinyl functionalized tethered oligunucleotides i.e. R/S serinyl functionalized tethered oligonucleotides and the process of preparation thereof. Specifically, the present invention provides a modified nucleoside unit containing the R/S serinyl derivative at 2? of the sugar unit which is introduced in a nucleotide sequence. Also, capping of the oligonucleotides with abasic serinyl derivative to render the nuclease stability to the oligonucleotiedds is also disclosed. The chiral serinyl functionalized tethered oligonucleotides, 2?-O-[R/S-(2-amino-3-methoxy)propyl] nucleic acids with both ?3- and 5?-ends capped with two units of abasic serine have antisense activity against the miRNA.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: March 20, 2018
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Vaijayanti Anil Kumar, Venubabu Kotikam, Souvik Maiti, Smita Nahar
  • Patent number: 9913856
    Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: March 13, 2018
    Assignee: ASTEX PHARMACEUTICALS, INC.
    Inventors: Rajashree Joshi-Hangal, Chunlin Tang, Sanjeev Redkar, Harish Ravivarapu
  • Patent number: 9856284
    Abstract: The present application relates to solid state forms, for example, crystalline forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: January 2, 2018
    Assignee: Alios BioPharma, Inc.
    Inventors: Anuj K Kuldipkumar, Ales Medek, Lori Ann Ferris, Praveen Mudunuri, Young Chun Jung, David Richard Willcox, Michael Waldo, William Aloysius Nugent
  • Patent number: 9844561
    Abstract: Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood lipid levels, age-related decreases in insulin sensitivity, age-related decreases in memory function, and age-related changes in eye function such as macular degeneration. The methods comprise administering nicotinamide mononucleotide (NMN) to a subject. In some embodiments, the administration can be oral administration. Also disclosed are pharmaceutical compositions comprising NMN.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: December 19, 2017
    Assignee: Washington University
    Inventors: Shin-ichiro Imai, Rajendra Apte
  • Patent number: 9833431
    Abstract: The present invention relates to pharmaceutical combinations comprising aminoacetonitrile derivatives and anticancer compounds. Further, the present invention relates to these pharmaceutical combinations for use in the treatment of cancer.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: December 5, 2017
    Assignee: Pitney Pharmaceuticals Pty Limited
    Inventors: David Lawson Morris, Mohammad Hossein Pourgholami, Roger Aston
  • Patent number: 9834576
    Abstract: The present invention relates to methods and intermediates for synthesizing 2?-deoxy-2?,2?-difluorotetrahydrouridine compounds.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: December 5, 2017
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hyeong-wook Choi, Steven Mathieu, Frank Fang, Bryan Matthew Lewis
  • Patent number: 9808474
    Abstract: Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: November 7, 2017
    Assignee: Abbott Laboratories
    Inventors: Rachael Buck, Geralyn O. Duska-McEwen, Joseph P. Schaller
  • Patent number: 9796641
    Abstract: The present invention relates to a method for stabilizing radiosynthetic intermediates used in synthesis of 18F radiolabeled aromatic amino acid derivatives toward decomposition caused by beta and gamma radiations by the use of radical scavengers and/or reductants and/or antioxidants.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: October 24, 2017
    Assignee: Trasis S.A.
    Inventors: Muhammad Otabashi, Gauthier Philippart, Samuel Voccia, Ludovic Wouters, Jean-Luc Morelle
  • Patent number: 9795625
    Abstract: The present invention relates to the new indications of chronic obstructive pulmonary disease (COPD) and idiophathic lung fibrosis (IPF) for uridine and uridine analogs.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: October 24, 2017
    Assignee: Universitaetsklinikum Freiburg
    Inventors: Marco Idzko, Stephan Sorichter
  • Patent number: 9783567
    Abstract: The invention provides synthetic processes and synthetic intermediates that can be used to prepare compounds having useful anti-HIV properties.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: October 10, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Richard Hung Chiu Yu, Brandon Heath Brown, Richard P. Polniaszek, Benjamin R. Graetz, Keiko Sujino, Duong Tran, Alan Scott Triman, Kenneth M. Kent, Steven Pfeiffer
  • Patent number: 9783541
    Abstract: The subject matter of the present invention is compounds which have a 6-aminopurine backbone corresponding to formula (I): in which R1, R2, R3, X, Y and Z are as defined in any one of claims 1 to 5, and Ar is a biphenyl or a naphthyl which may be substituted with R3, for use in the treatment of cancer.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: October 10, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS, HOSPICES CIVILS DE LYON, ECOLE NORMALE SUPERIEURE DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, UNIVERSITE DE MONTPELLIER 1
    Inventors: Laurent Chaloin, Suzanne Peyrottes, Corinne Lionne, Zsuzsanna Marton, David Egron, Remi Guillon, Christian Perigaud, Charles Dumontet, Lars Petter Jordheim, Isabelle Krimm
  • Patent number: 9763971
    Abstract: The invention relates to a composition for use in the treatment or prevention of recognition dysfunction, and/or for improving recognition, in a (prodromal) Alzheimer's patient, in particular in a drug-naive (prodromal) Alzheimer's patient, more particularly in a subject with a mini-mental state examination of 20-30.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: September 19, 2017
    Assignee: N.V. Nutricia
    Inventors: Martine Groenendijk, Anke Bongers
  • Patent number: 9765107
    Abstract: The present invention relates to Cyclic Phosphonate Substituted Nucleoside Derivatives of Formula (I): (structure) and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2 and R3 are as defined herein, as well as to compositions and methods of using the Cyclic Phosphonate Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: September 19, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Stephane Bogen, Vinay Girijavallabhan, Quang Truong, Ping Chen, Frank Bennett, Angela Kerekes, Qun Dang, David B. Olsen, Ian Davies
  • Patent number: 9765328
    Abstract: The present invention provides stable, nuclease-resistant TNA and TNA-DNA oligonucleotides, wherein the oligonucleotides are completely resistant to enzymatic degradation for at least 24-72 hours. Methods of synthesis and use in diagnostic and therapeutic applications are also provided. Specifically, in one embodiment, we describe the chemical and biological stability of TNA and mixed-backbone (mosaic) TNA-DNA oligonucleotides under a variety of conditions and sequence contexts.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: September 19, 2017
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventor: John Chaput
  • Patent number: 9757405
    Abstract: Use of rutin for increasing the effectiveness of chemotherapeutic treatments used in human and veterinary medicine for the treatment of tumors is described, in particular in case of resistance to chemotherapeutics currently in use.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: September 12, 2017
    Assignee: PROBIOTICAL S.P.A.
    Inventors: Franco Frascini, Marcello Iriti, Paolo Maestri, Lia Rimondini, Enrico Catalano, Saverio Megna
  • Patent number: 9758546
    Abstract: Provided herein are methods for the synthesis of oligomeric compounds wherein removal of the 5?-terminal trityl group is performed at reduced temperature and lower pH relative to standard methods. In certain embodiments, the present methods provide detritylated oligomeric compounds having a reduced percentage of depurination relative to the same detritylated oligomeric compounds prepared using standard methods. In certain embodiments, the present methods provide detritylated oligomeric compounds with increased purity relative to the same detritylated oligomeric compounds prepared using standard methods. In certain embodiments, the present method provide an increased rate of detritylation compared to standard methods.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: September 12, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Dana Chreng
  • Patent number: 9757408
    Abstract: The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine N1-oxide or a derivative thereof as an effective ingredient.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: September 12, 2017
    Assignee: HAYASHIBARA CO., LTD.
    Inventors: Keizo Kohno, Emiko Ohashi, Hajime Kusano, Shigeharu Fukuda, Tatsuya Ishihara
  • Patent number: 9758544
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: September 12, 2017
    Assignee: Alios BioPharma, Inc.
    Inventors: Leonid Beigelman, David Bernard Smith, Guangyi Wang, Natalia Dyatkina